Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.
On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.
Last year's bear market made many victims among even the most prominent corporations although growth stocks fared even worse than other categories of equities. Among this small group of outperformers are two healthcare leaders: biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) and medical device expert DexCom (NASDAQ: DXCM). Let's consider why Vertex Pharmaceuticals and DexCom are excellent stocks to buy.